Subcutaneous rapid-acting insulin analogues for diabetic ketoacidosis

Cochrane Database of Systematic Reviews

Volumn 2016, Issue 1, 2016, Pages

  Andrade Castellanos, Carlos A ^a   Colunga Lozano, Luis Enrique ^a   Delgado Figueroa, Netzahualpilli ^a   Gonzalez Padilla, Daniel A ^b  

^a HOSPITAL CIVIL DE GUADALAJARA FRAY ANTONIO ALCALDE   (Mexico)

^b HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN ASPART; INSULIN LISPRO; PIG INSULIN; SHORT ACTING INSULIN; ANTIDIABETIC AGENT; INSULIN;

BIBLIOGRAPHIC DATABASE; DIABETIC KETOACIDOSIS; DIABETIC PATIENT; EMERGENCY WARD; FOLLOW UP; GLUCOSE BLOOD LEVEL; HOSPITAL MORTALITY; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN INFUSION; INTENSIVE CARE UNIT; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PATIENT SATISFACTION; PREGNANCY DIABETES MELLITUS; PREGNANT WOMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SYSTEMATIC REVIEW; SYSTEMATIC REVIEW (TOPIC); ADULT; CHILD; META ANALYSIS; SUBCUTANEOUS DRUG ADMINISTRATION; YOUNG ADULT;

ADULT; CHILD; DIABETIC KETOACIDOSIS; HUMANS; HYPOGLYCEMIC AGENTS; INJECTIONS, SUBCUTANEOUS; INSULIN; INSULIN ASPART; INSULIN LISPRO; INSULIN, SHORT-ACTING; RANDOMIZED CONTROLLED TRIALS AS TOPIC; YOUNG ADULT;

EID: 84966389696     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD011281.pub2     Document Type: Review

References (66)

1. Della Manna T, Steinmetz L, Campos PR, Farhat SC, Schvartsman C, Kuperman H, et al. Subcutaneous use of a fast-acting insulin analog: an alternative treatment for pediatric patients with diabetic ketoacidosis. Diabetes Care 2005;28(8):1856-61.
2. Ersöz HO, Ukinc K, Köse M, Erem C, Gunduz A, Hacihasanoglu AB, et al. Subcutaneous lispro and intravenous regular insulin treatments are equally effective and safe for the treatment of mild and moderate diabetic ketoacidosis in adult patients. International Journal of Clinical Practice 2006;60(4):429-33.
3. Karoli R, Fatima J, Salman T, Sandhu S, Shankar R. Managing diabetic ketoacidosis in non-intensive care unit setting: Role of insulin analogs. Indian Journal of Pharmacology 2011;43(4):398-401.
4. Umpierrez GE, Latif K, Stoever J, Cuervo R, Park L, Freire AX, et al. Efficacy of subcutaneous insulin lispro versus continuous intravenous regular insulin for the treatment of patients with diabetic ketoacidosis. American Journal of Medicine 2004;117(5):291-6.
5. Umpierrez GE, Cuervo R, Karabell A, Latif K, Freire AX, Kitabchi AE. Treatment of diabetic ketoacidosis with subcutaneous insulin aspart. Diabetes Care 2004;27(8):1873-8.
6. Adesina OF, Kolawole BA, Ikem RT, Adebayo OJ, Soyoye DO. Comparison of lispro insulin and regular insulin in the management of hyperglycaemic emergencies. African Journal of Medicine and Medical Sciences 2011;40:59-66.
7. Armor B, Harrison D, Lawler F. Assessment of the clinical outcome of a symptom-based outpatient hyperglycemia protocol. Diabetes Therapy 2011;2:67-80.
8. Attia N, Jones TW, Holcombe J, Tamborlane WV. Comparison of human regular and lispro insulins after interruption of continuous subcutaneous insulin infusion and in the treatment of acutely decompensated IDDM. Diabetes Care 1998;5:817-21.
9. Fisher JN, Shahshahani MN, Kitabchi AE. Diabetic ketoacidosis: low-dose insulin therapy by various routes. The New England Journal of Medicine 1977;297(5):238-41.
10. Hsia E, Seggelke S, Draznin B. Novel insulin infusion protocol: Subcutaneous administration of long-acting insulin during insulin infusion prevents rebound hyperglycemia. Diabetes 2011;60:A262.
11. Kadowaki T, Nishida T, Kaku K. 28-week, randomised, multicenter, open-label, parallel-group phase III trial to investigate the efficacy and safety of biphasic insulin aspart 70 thrice-daily injections vs twice-daily injections of biphasic insulin aspart 30 in patients with type 2 diabetes. Journal of Diabetes Investigation 2010;1(3):103-10.
12. Liu J, Jia Z, Zhang B, Hong LV, Zhang G, Tan B, et al. Insulin pump in the treatment of diabetic ketoacidosis. Chinese Journal of Emergency Medicine 2006;15:460-1.
13. NCT00467246. Sub-cutaneous insulin in hyperglycaemic emergencies. https://www.clinicaltrials.gov/ct2/show/NCT00467246 (last accessed 4 December 2015).
14. NCT01365793. Randomized control trial of fluid therapy for pediatric diabetic ketoacidosis. https://www.clinicaltrials.gov/ct2/show/NCT01365793 (last accessed 4 December 2015).
15. NCT02006342. Effectiveness of subcutaneous glargine on the time to closure of the anion gap in patients presenting to the emergency department with diabetic keto-acidosis (GT-COG). https://www.clinicaltrials.gov/ct2/show/NCT02006342 (accessed 4 December 2015).
16. Philotheou A, Arslanian S, Blatniczky L, Peterkova V, Souhami E, Danne T. Comparable efficacy and safety of insulin glulisine and insulin lispro when given aspart of a Basal-bolus insulin regimen in a 26-week trial in pediatric patients with type1 diabetes. Diabetes Technology & Therapeutics 2011;3:327-34.
17. Savoldelli RD, Farhat SC, Manna TD. Alternative management of diabetic ketoacidosis in a Brazilian pediatric emergency department. Diabetology & Metabolic Syndrome 2010;2:41.
18. Umpierrez GE, Jones S, Smiley D, Mulligan P, Keyler T, Temponi A, et al. Insulin analogs versus human insulin in the treatment of patients with diabetic ketoacidosis: a randomized controlled trial. Diabetes Care 2009;7:1164-9.
19. Vincent M, Nobécourt E. Treatment of diabetic ketoacidosis with subcutaneous insulin lispro: a review of the current evidence from clinical studies. Diabetes & Metabolism 2013;39(4):299-305.
20. Weinzimer SA, Ternand C, Howard C, Chang CT, Becker DJ, Laffel LM. A randomized trial comparing continuous subcutaneous insulin infusion of insulin aspart versus insulin lispro in children and adolescents with type 1 diabetes. Diabetes Care 2008;31(2):210-5.
21. Yanai H, Adachi H, Hamasaki H. Diabetic ketosis caused by the insulin analog aspart-induced anti-insulin antibody: successful treatment with the newest insulin analog glulisine. Diabetes Care 2011;34(6):e108.
22. El Ebrashy I, El Hefnawy MHMF, Basyouni A, Mahfouz H. Subcutaneous use of rapid insulin analog: an alternative treatment for patients with mild to moderate diabetic ketoacidosis. Pediatric Diabetes 2010;11(Suppl 14):32 (O/6/FRI/01).
23. NCT00920725. Subcutaneous aspart insulin to treat diabetic ketoacidosis (DKA) and beta-hydroxybutyrate testing in DKA. https://www.clinicaltrials.gov/ct2/show/NCT00920725 (last accessed 4 December 20015).
24. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1999;22(Suppl 1):S5-19.
25. American Diabetes Association. Hyperglycemic crises in diabetes. Diabetes Care 2004;27(Suppl 1):S94-102.
26. American Diabetes Association. Standards of medical care in diabetes - 2008. Diabetes Care 2008;31(Suppl 1):S12-54. [PUBMED: 18165335]
27. Alberti KG, Hockaday TD, Turner RC. Small doses of intramuscular insulin in the treatment of diabetic "coma". The Lancet 1973;2(7828):515-22.
28. Anderson RT, Skovlund SE, Marrero D, Levine DW, Meadows K, Brod M, et al. Development and validation of the insulin treatment satisfaction questionnaire. Clinical Therapeutics 2004;26(4):565-78.
29. Basu A, Close CF, Jenkins D, Krentz AJ, Nattrass M, Wright AD. Persisting mortality in diabetic ketoacidosis. Diabetic Medicine 1993;10:282-4.
30. Beller EM, Chen JK, Wang UL, Glasziou PP. Are systematic reviews up-to-date at the time of publication?. Systematic Reviews 2013;2(1):36.
31. Dave J, Chatterjee S, Davies M, Higgins K, Morjaria H, McNally P, et al. Evaluation of admissions and management of diabetic ketoacidosis in a large teaching hospital. Practical Diabetes International 2004;21(4):149-53.
32. Faich GA, Fishbein HA, Ellis SE. The epidemiology of diabetic acidosis: a population-based study. American Journal of Epidemiology 1983;117(5):551-8.
33. Hemkens LG, Grouven U, Bender R, Günster C, Gutschmidt S, Selke GW, et al. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia 2009;52(9):1732-44.
34. Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Statistics in Medicine 2002;21:1539-58.
35. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analysis. BMJ 2003;327:557-60.
36. Higgins JPT, Thompson SG, Spiegelhalter DJ. A re-evaluation of random-effects meta-analysis. Journal of the Royal Statistical Society: Series A (Statistics in Society) 2009;172(1):137-59.
37. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
38. Higgins JPT, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomized trials. BMJ 2011;343:d5928.
39. Home PD, Lindholm A, Riis A, European Insulin Aspart Study Group. Insulin aspart vs. human insulin in the management of long-term blood glucose control in Type 1 diabetes mellitus: a randomized controlled trial. Diabetic Medicine 2000;17(11):762-70.
40. Home PD. The pharmacokinetics and pharmacodynamics of rapid-acting insulin analogues and their clinical consequences. Diabetes, Obesity & Metabolism 2012;14(9):780-8.
41. Howey DC, Bowsher RR, Brunelle RL, Rowe HM, Santa PF, Downing-Shelton J, et al. [Lys(B28), Pro(B29)]-human insulin: effect of injection time on postprandial glycemia. Clinical Pharmacology and Therapeutics 1995;58(4):459-69.
42. Hróbjartsson A, Thomsen AS, Emanuelsson F, Tendal B, Hilden J, Boutron I, et al. Observer bias in randomized clinical trials with measurement scale outcomes: a systematic review of trials with both blinded and nonblinded assessors. Canadian Medical Association Journal 2013;185(4):E201-11.
43. Johnson DD, Palumbo PJ, Chu CP. Diabetic ketoacidosis in a community-based population. Mayo Clinic Proceedings 1980;55(2):83-8.
44. Kim S. Burden of hospitalizations primarily due to uncontrolled diabetes: implications of inadequate primary health care in the United States. Diabetes Care 2007;30(5):1281-2.
45. Kirkham JJ, Dwan KM, Altman DG, Gamble C, Dodd S, Smyth R, et al. The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews. BMJ 2010;340:c365. [DOI: 10.1136/bmj.c365]
46. Kitabchi AE, Umpierrez GE, Murphy MB, Barrett EJ, Kreisberg RA, Malone JI, et al. Management of hyperglycemic crises in patients with diabetes. Diabetes Care 2001;24:131-53.
47. Kitabchi AE, Umpierrez GE, Miles JM, Fisher JN. Hyperglycemic crises in adult patients with diabetes. Diabetes Care 2009;32(7):1335-43.
48. Kurtzhals P, Schäffer L, Sørensen A, Kristensen C, Jonassen I, Schmid C, et al. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 2000;49(6):999-1005.
49. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA, et al. The PRISMA statement for reporting systematic and meta-analyses of studies that evaluate interventions: explanation and elaboration. PLoS Medicine 2009;6(7):1-28. [DOI: 10.1371/journal.pmed.1000100]
50. Luzi L, Barrett EJ, Groop LC, Ferrannini E, DeFronzo RA. Metabolic effects of low-dose insulin therapy on glucose metabolism in diabetic ketoacidosis. Diabetes 1988;37(11):1470-7.
51. Malone ML, Gennis V, Goodwin JS. Characteristics of diabetic ketoacidosis in older versus younger adults. Journal of the American Geriatrics Society 1992;40(11):1100-4.
52. Mathiesen ER, Kinsley B, Amiel SA, Heller S, McCance D, Duran S, et al. Maternal glycemic control and hypoglycemia in type 1 diabetic pregnancy: a randomized trial of insulin aspart versus human insulin in 322 pregnant women. Diabetes Care 2007;30(4):771-6.
53. Mazer M, Chen E. Is subcutaneous administration of rapid-acting insulin as effective as intravenous insulin for treating diabetic ketoacidosis?. Annals of Emergency Medicine 2009;53(2):259-63.
54. Meader N, King K, Llewellyn A, Norman G, Brown J, Rodgers M, et al. A checklist designed to aid consistency and reproducibility of GRADE assessments: development and pilot validation. Systematic Reviews 2014;3:82.
55. Muir AB, Quisling RG, Yang MC, Rosenbloom AL. Cerebral edema in childhood diabetic ketoacidosis: natural history, radiographic findings, and early identification. Diabetes Care 2004;27(7):1541-6.
56. Nyenwe EA, Kitabchi AE. Evidence-based management of hyperglycemic emergencies in diabetes mellitus. Diabetes Research and Clinical Practice 2011;94(3):340-51.
57. Rayman G, Profozic V, Middle M. Insulin glulisine imparts effective glycaemic control in patients with Type 2 diabetes. Diabetes Research and Clinical Practice 2007;76(2):304-12.
58. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
59. Riley RD, Higgins JP, Deeks JJ. Interpretation of random effects meta-analyses. BMJ 2011;342:d549.
60. Roach P. New insulin analogues and routes of delivery: pharmacodynamic and clinical considerations. Clinical Pharmacokinetics 2008;47(9):595-610.
61. Savage MW, Dhatariya KK, Kilvert A, Rayman G, Rees JA, Courtney CH, et al. Joint British Diabetes Societies guideline for the management of diabetic ketoacidosis. Diabetic Medicine 2011;28(5):508-15.
62. Siebenhofer A, Plank J, Berghold A, Jeitler K, Horvath K, Narath M, et al. Short acting insulin analogues versus regular human insulin in patients with diabetes mellitus. Cochrane Database of Systematic Reviews 2006, Issue 2. [DOI: 10.1002/14651858.CD003287]
63. Sterne JA, Sutton AJ, Ioannidis JP, Terrin N, Jones DR, Lau J, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomized controlled trials. BMJ 2011;343:d4002.
64. Warner DP, Mckinney PA, Law GR, Bodansky HJ. Mortality and diabetes from a population based study in Yorkshire. Archives of Disease in Childhood 1998;78:435-8.
65. Alberti KM, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part I: diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation. Diabetic Medicine 1998;15:539-53.
66. Wood L, Egger M, Gluud LL, Schulz KF, Juni P, Altman DG, et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ 2008;336(7644):601-5.